ABSTRACT
Tuberculosis is increasing in France, particularly in district of Paris. This resurgence is attributed, in part, to the acquired immune deficiency syndrome (AIDS) epidemic infection, but also to the worsening of the social and economic conditions of a increasingly and more and more excluded part of the population. The non compliance to the treatment is the most problem among this population and explains the high rate or the lost from follow up patients and relapses. Several solutions are proposed to improve the compliance to the treatment, which remains one of the principal measures of the fight against tuberculosis.
Subject(s)
Cyclosporins/therapeutic use , Uveitis/drug therapy , Adult , Cyclosporins/adverse effects , Eye Diseases/drug therapy , Female , Humans , Optic Disk , RecurrenceSubject(s)
Cyclosporins/therapeutic use , Uveitis/drug therapy , Adult , Female , Humans , Optic Disk , Recurrence , Time Factors , Vision Disorders/etiologyABSTRACT
The authors have carried during one year, in the hospital of Villeneuve-Saint-Georges, a prospective study on 229 cases of pneumococcal infections with bacteriological findings. They emphazise the frequency, the high-exposed groups and the gravity of these infections despite of the antibiotherapy. The emergence of multiply resistant pneumococcus makes out another argument for proposing a preventive vaccination taking notice of the most frequent serotypes found in France.
Subject(s)
Pneumococcal Infections/epidemiology , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Drug Resistance, Microbial , Female , France , Hospitals, General , Humans , Immunotherapy , Infant , Infant, Newborn , Male , Middle Aged , Pneumococcal Infections/prevention & control , Prospective Studies , SerotypingABSTRACT
The frequency of non soil dwelling anaerobic infections is increasing. The authors report 33 cases of Bacteroides fragilis bacteremias, and study the responsabilities of different factors of prognosis (especially age and underlying conditions). Nitroimidazoles are very active against all Bacteroides fragilis. This therapy is the drug of choice for such infections.
